FDA approves Oxford BioMedica’s UshStat IND to treat Usher syndrome type 1B

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration has approved its Investigational New Drug application for the Phase I/IIa clinical development of UshStat, a novel gene-based treatment for Usher syndrome type 1B.

Full Story →